ALLMedicine™ Alpha1-antitrypsin Deficiency Center

Oct 19th, 2022 - Alpha-1 antitrypsin deficiency (AATD) is a genetic disease caused by a hepatic accumulation of mutant alpha-1 antitrypsin (ZAAT). Individuals with AATD are prone to develop a chronic liver disease that remains undiagnosed until late stage of the d...

Aug 16th, 2022 - The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 144 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in ...

Jun 25th, 2022 - Alpha1-antitrypsin (AAT) deficiency results from carriage of a homozygous SERPINA1 "Z" mutation (proteinase inhibitor [PI] ZZ). The Z allele produces a mutant AAT protein called Z-AAT, which accumulates in hepatocytes and can lead to progressive l...

May 13th, 2022 - Practice Essentials Vilanova disease, or subacute nodular migratory panniculitis, was first observed in 1954[1] and then named by Vilanova and Pinol Aguade in 1956.[2] Vilanova's original 14 patients were all women, most of whom were in their fift...

May 13th, 2022 - Practice Essentials Vilanova disease, or subacute nodular migratory panniculitis, was first observed in 1954 [1] and then named by Vilanova and Pinol Aguade in 1956. [2] Vilanova's original 14 patients were all women, most of whom were in their fi...

Aug 16th, 2022 - The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 144 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in ...

Oct 28th, 2021 - This study is a multicenter, open-label trial to evaluate the safety and pharmacokinetics of weekly intravenous (IV) infusions of 60 mg/kg of the investigational drug in participants with alpha1-antitrypsin deficiency (AATD). The trial will be con...

Oct 5th, 2020 - GLASSIA (human alpha-1 proteinase inhibitor (A1PI), also known as human alpha-1 antitrypsin, Kamada-AAT or Kamada-API) is a, liquid, ready-to-use preparation of human A1PI. Alpha-1 proteinase inhibitor belongs to the family of serine proteinase in...

May 31st, 2017 - Alpha1-antitrypsin deficiency (AAT deficiency) is a frequently overlooked metabolic disorder. Apart from lung disease, AAT deficiency also leads to liver disease. This can affect people of all ages and all ethnic groups. Although involvement of th...

Mar 25th, 2016 - BACKGROUND: Severe congenital deficiency for alpha1-antitrypsin is associated with the early onset of emphysema, usually by the third decade of life. One approach to correct this deficiency is though replacement with alpha1-antitrypsin (referred t...

May 2nd, 2016 - WASHINGTON, DC — For people who undergo lung transplantation, mortality risk is only slightly higher when donors are 55 to 64 years of age than when they are younger than 55 years, the current age recommendation, according to an analysis of the wo...

May 27th, 2008 - May 27, 2008 — Alpha1-antitrypsin deficiency (AATD) can greatly increase the risk for lung cancer, researchers report. AATD carriers might have a risk of developing lung cancer that is 70% higher than that for noncarriers, according to new data pu...

May 27th, 2008 - May 27, 2008 — Alpha1-antitrypsin deficiency (AATD) can greatly increase the risk for lung cancer, researchers report. AATD carriers might have a risk of developing lung cancer that is 70% higher than that for noncarriers, according to new data pu...

(Reuters Health) - The experimental Arrowhead Pharmaceuticals drug fazirsiran can reduce the accumulation of a mutant protein by 83% among people with alpha1-antitrypsin deficiency (AAT) disease, according to results from an open-label phase 2 tri...